Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Assets ($M)
  • Employees

In Ian Read’s final year as the company’s CEO, Pfizer managed to grow revenues by just 2% as it adjusted to greater competition to—and diminished sales of—Viagra and other drugs on which the company lost patent exclusivity in 2017. The pharmaceutical giant is now in the midst of a reorganization since announcing in the summer of 2018 that it would separate its business into three parts, one of which (its consumer health division) it plans to merge into a joint venture with GlaxoSmithKline. The moves are designed to position Pfizer for greater sales growth under new CEO Albert Bourla.

Company Info

Albert Bourla
CEO Title
Chief Executive Officer & Director
Health Care
HQ Location
New York, N.Y.
Years on Fortune 500 List65
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Pfizer Rank History


Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$53,647.02.1%
Profits ($M)$11,153.0-47.7%
Assets ($M)$159,422.0-
Total Stockholder Equity ($M)$63,407.0-

Profit Ratios

Profit as % of Revenues20.8%
Profits as % of Assets7.0%
Profits as % of Stockholder Equity17.6%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)1.87
EPS % Change (from 2017)-46.9%
EPS % Change (5 year annual rate)-10.1%
EPS % Change (10 year annual rate)4.5%

Total Return

Total Return to Investors (2018)24.7%
Total Return to Investors (5 year, annualized)11.2%
Total Return to Investors (10 year, annualized)13.8%